Valley Fever Market Report 2025

The valley fever market size has grown strongly in recent years. It will grow from $0.99 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to factors such as the increasing effects of climate change driving the spread of fungal infections, rising research funding for Valley Fever treatments, greater investments in healthcare, growing demand for specialized diagnostic laboratories, and a rising incidence of Valley Fever in non-endemic regions.

The valley fever market size is expected to see strong growth in the next few years. It will grow to $1.29 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The projected growth during the forecast period can be attributed to factors such as the increasing adoption of telemedicine, a rise in research on antifungal resistance, growing funding for vaccine development, higher population movement across high-risk areas, and the expanding availability of antifungal treatments. Key trends expected in this period include technological innovations, a surge in demand for antifungal drugs, advancements in vaccine development, the continued growth of telemedicine, and enhanced cross-border collaboration.

The increasing exposure to fungus spores is expected to drive the growth of the valley fever market. Fungus spores are tiny reproductive units produced by fungi that can spread through air, water, or surfaces, allowing the fungus to grow and reproduce in new environments. Exposure to these spores has been rising due to factors such as deforestation and shifting weather patterns, which disrupt the soil and promote the release of spores. This leads to a higher risk of infections such as valley fever, particularly in arid regions where the coccidioides fungus thrives. Valley fever treatments help those exposed to fungal spores by alleviating symptoms, preventing complications, and controlling fungal growth, ultimately improving recovery and quality of life. For example, in September 2024, the International Society for Infectious Diseases reported that invasive fungal infections affect about 6.5 million people annually, causing nearly 3.8 million deaths, with approximately 2.5 million deaths directly related to these infections. Therefore, the rising exposure to fungus spores is fueling the growth of the valley fever market.

The growth of healthcare facilities is anticipated to boost the valley fever market. Healthcare facilities refer to the essential infrastructure, systems, and resources required to provide effective healthcare services. The expansion of healthcare infrastructure is driven by advances in medical technology, as innovations such as telemedicine, robotic surgery, and AI-driven diagnostics require upgraded facilities, specialized equipment, and improved healthcare delivery systems to enhance patient outcomes and operational efficiency. These facilities support the treatment of valley fever by offering early diagnosis, antifungal treatments, patient education, and ongoing care to manage symptoms and prevent complications. For instance, the American Hospital Association reported that in 2024, there were 6,120 hospitals in the United States, up from 6,093 in 2022. As a result, the growth in healthcare infrastructure is driving the expansion of the valley fever market.

Companies in the valley fever market are focusing on developing innovative vaccines to combat the growing threat of fungal infections. These vaccines aim to protect individuals by using advanced scientific methods and manufacturing techniques, which enhance public health and safety. For instance, in August 2024, Anivive Lifesciences Inc., a U.S.-based pet pharmaceutical company, received a contract worth up to $33 million from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a human vaccine for valley fever. The funding will support further manufacturing, formulation, extensive safety testing, and a Phase 1 clinical trial, with the goal of delivering the first vaccine to prevent this serious systemic fungal infection.

Major players in the valley fever market are Merck & Co. Inc., Fresenius Kabi, Dr. Reddy's Laboratories, Horster Life Science, Mankind Pharma, Atom Pharma, Ravoos Laboratories, Casca Remedies, Hema Pharmaceuticals, Globela Pharma, Spansules Pharmatech, Sanes Pharmaceuticals, CDH Chemicals, Sainor Laboratories, Maithili Life Sciences, Stratechem (I) Pvt. Ltd., Shantam Pharma, Cerata Pharmaceuticals, Aden Healthcare, Kabir Lifesciences.

North America was the largest region in the valley fever market in 2024. The regions covered in valley fever report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Valley Fever market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Valley fever, also known as coccidioidomycosis, is a fungal infection that mainly affects the lungs, causing symptoms such as cough, fever, fatigue, and chest pain. In some cases, it can lead to severe complications. The infection is caused by inhaling airborne spores from the coccidioides fungi, which are commonly found in dry, dusty soil and become airborne when the soil is disturbed.

The primary treatment options for valley fever include fluconazole, itraconazole, voriconazole, posaconazole, and others. Fluconazole is an antifungal medication that works by inhibiting the growth of fungi to treat fungal infections. The infection can affect various sites, including the skin, lungs, liver, bones, heart, brain, and the membranes surrounding the brain and spinal cord. These treatments are used for a range of end-users, including humans, cattle, sheep, goats, camels, and others.

The valley fever market research report is one of a series of new reports that provides valley fever market statistics, including valley fever industry global market size, regional shares, competitors with a valley fever market share, detailed valley fever market segments, market trends and opportunities, and any further data you may need to thrive in the valley fever industry. This valley fever market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The valley fever market consists of sales of antifungal medications and steroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.